Rare Patient Voice Surveys
Rare Patient Voice, LLC connects patients and family caregivers of rare and non-rare diseases with opportunities to share their opinions with companies and researchers by participating in all types of research studies. These include surveys and phone interviews, online bulletin boards, focus groups, clinical trials, and more.
Link to Register: rarepatientvoice.com/nationalataxiafoundation
About the Study
Eligible Ataxia Types
Multiple forms of Ataxia, varies by survey
Type of Study
Survey
Clinical Trial Phase
N/A
Age Range
Adult 18+
What does participation in the study entail?
Varies by survey. Please see individual survey listings at Rare Patient Voice for details.
What are the potential benefits for participants?
Varies by survey. Please see individual survey listings at Rare Patient Voice for details.
What are the potential risks for participants?
Please see individual survey listings at Rare Patient Voice for details.
Is there financial compensation?
Yes. The exact amount varies by survey. Please see individual survey listings at Rare Patient Voice for details.
Is there travel reimbursement?
Not applicable.
Who is eligible?
Varies by survey. Please see individual survey listings at Rare Patient Voice for details.
Additional Information or Resources
Link to Register: rarepatientvoice.com/nationalataxiafoundation
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
